Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 12/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | MLNR | O43193 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | MC3R | P41968 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15295668 | 0.88 | SYK (0.37) | SLC2A1KDM4ECYP1A2CYP3A4CYP2D6 | |
| Picumeterol SCHEMBL156907 | 0.88 | SLC2A1 (0.57) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| Picumeterol SCHEMBL29414334 | 0.88 | SLC2A1 (0.57) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| Picumeterol SCHEMBL9857897 | 0.88 | SLC2A1 (0.57) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| Picumeterol SCHEMBL83175 | 0.88 | SLC2A1 (0.57) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| SCHEMBL10416913 | 0.88 | SLC2A1 (0.57) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| SCHEMBL10391329 | 0.87 | SLC2A1 (0.57) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| SCHEMBL8743863 | 0.84 | ADRB2 (0.48) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| SCHEMBL10416519 | 0.84 | SLC2A1 (0.59) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| SCHEMBL9741835 | 0.84 | SLC2A1 (0.57) | SLC2A1ADRB2ADRB1SLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253047-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180055852-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20170369511-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9655892-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160185800-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160158239-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2016-06-09 | — | — | US | disclosed |
| US-9216982-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-8993580-B2 | Benzothiazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140341894-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2014-11-20 | — | — | US | disclosed |
| US-20140057844-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2014-02-27 | — | — | US | disclosed |
| EP-2311793-A1 | Crystalline levosalbutamol sulphate (Form II) | Cipla Ltd. (IN) | 2011-04-20 | — | — | EP | disclosed |
| US-20090263333-A1 | Pharmaceutical compounds and compositions | CIPLA LIMITED | 2009-10-22 | — | — | US | disclosed |
| WO-2007034207-A2 | TROVENTOL FORMULATION | CIPLA LIMITED (IN) | 2007-03-29 | — | — | WO | disclosed |
| US-20040136920-A1 | Medicaments | GLAXO GROUP LIMITED (GB) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | SLC2A1 4691/4885ADRB2 4142/4885ADRB1 3619/4885 |
| US-20090263333-A1 | Pharmaceutical compounds and compositions | ADRB3, ADRB2, ADRA2C | SLC2A1 3725/4885ADRB2 2/4885ADRB1 5/4885 |
| US-20170369511-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | SLC2A1 3358/4885ADRB2 3061/4885ADRB1 2885/4885 |
| US-20160185800-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | SLC2A1 4464/4885ADRB2 3995/4885ADRB1 3593/4885 |
| US-20140341894-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | SLC2A1 4344/4885ADRB2 4155/4885ADRB1 4051/4885 |
| US-10253047-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | SLC2A1 4083/4885ADRB2 2364/4885ADRB1 2061/4885 |
| US-20160158239-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | SLC2A1 4344/4885ADRB2 4155/4885ADRB1 4051/4885 |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | KRAS, NRAS, HRAS | SLC2A1 4691/4885ADRB2 4142/4885ADRB1 3619/4885 |
| US-20180055852-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | SLC2A1 3358/4885ADRB2 3061/4885ADRB1 2885/4885 |
| US-20140057844-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | RPL30, EIF4E, EIF4EBP1 | SLC2A1 4498/4885ADRB2 4859/4885ADRB1 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.